Biorestorative Therapies (BRTX) Stock Price, News & Analysis

Company Overview

Biorestorative Therapies Inc (NASDAQ: BRTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of regenerative tissue therapy products. The company leverages a proprietary universal allogeneic cell technology platform to create high-potency cell therapy candidates designed to promote tissue repair, reduce inflammation and accelerate healing in areas damaged by disease or medical treatment.

Its lead development program targets radiation-induced oral mucositis (RIOM), a painful and dose-limiting side effect experienced by head and neck cancer patients undergoing radiotherapy. Biorestorative Therapies’ candidate has completed early-stage clinical evaluation and is advancing through planned trials to assess safety and efficacy in reducing the duration and severity of oral mucositis. Preclinical studies have also been conducted to explore additional indications, including inflammatory and degenerative conditions.

Headquartered in Malvern, Pennsylvania, Biorestorative Therapies manages its research, manufacturing and clinical development activities in the United States. The company works with clinical research organizations and academic centers to support its ongoing trials and maintains a leadership team with experience spanning cell therapy, clinical development and regulatory affairs. Biorestorative Therapies continues to pursue partnerships to expand its pipeline and accelerate the path to potential regulatory approval.

Key Stats

• Today's Range: $0.37 to $0.39
• 50-Day Range: $0.17 to $0.48
• 52-Week Range: $0.16 to $1.89
• Volume: 91,764 shs
• Average Volume: 555,373 shs
• Market Capitalization: $9.48 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Biorestorative Therapies Stock Analysis - MarketRank™

Biorestorative Therapies scored higher than 14% of companies evaluated by MarketBeat, and ranked 789th out of 848 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Biorestorative Therapies has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Biorestorative Therapies has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Biorestorative Therapies are expected to grow in the coming year, from ($0.66) to ($0.52) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Biorestorative Therapies is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Biorestorative Therapies is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Biorestorative Therapies has a P/B Ratio of 9.31. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.82% of the float of Biorestorative Therapies has been sold short.

Short Interest Ratio / Days to Cover

Biorestorative Therapies has a short interest ratio ("days to cover") of 0.68, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Biorestorative Therapies has recently decreased by 80.55%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Biorestorative Therapies does not currently pay a dividend.

Dividend Growth

Biorestorative Therapies does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for BRTX on MarketBeat in the last 30 days. This is a decrease of -90% compared to the previous 30 days.

MarketBeat Follows

1 people have added Biorestorative Therapies to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Biorestorative Therapies insiders have not sold or bought any company stock.

Percentage Held by Insiders

13.60% of the stock of Biorestorative Therapies is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

69.38% of the stock of Biorestorative Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/14/2026
• Today: 7/07/2026
• Next Earnings (Estimated): 8/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:BRTX
• Previous Symbol: OTCMKTS:BRTX
• CIK: 1505497
• Web: www.biorestorative.com
• Phone: 631-760-8100
• Fax: N/A
• Employees: 7
• Year Founded: 1997

Profitability

• EPS (Trailing Twelve Months): ($1.07)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$14.24 million
• Net Margins: -3,088.27%
• Pretax Margin: -3,088.27%
• Return on Equity: -508.42%
• Return on Assets: -230.94%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.35
• Quick Ratio: 2.35

Sales & Book Value

• Annual Sales: $360 thousand
• Price / Sales: 26.34
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.04 per share
• Price / Book: 9.31

Miscellaneous

• Outstanding Shares: 25,480,000
• Free Float: 22,013,000
• Market Cap: $9.48 million
• Optionable: Not Optionable
• Beta: 0.73